AstraZeneca (AZN) Stock Forecast & Price Target

$67.76 +0.86 (+1.28%)

As of 01:50 PM Eastern

AstraZeneca - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 11 Analyst Ratings

Sell
0

Hold
1

Buy
10

Based on 11 Wall Street analysts who have issued ratings for AstraZeneca in the last 12 months, the stock has a consensus rating of "Buy." Out of the 11 analysts, 1 has given a hold rating, 8 have given a buy rating, and 2 have given a strong buy rating for AZN.

Consensus Price Target

$86.80
28.10% Upside

According to the 11 analysts' twelve-month price targets for AstraZeneca, the average price target is $86.80. The highest price target for AZN is $97.00, while the lowest price target for AZN is $75.00. The average price target represents a forecasted upside of 28.10% from the current price of $67.76.

Get the Latest News and Ratings for AZN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for AstraZeneca and its competitors.

AZN Analyst Ratings Over Time

Type	Current Forecast 4/22/24 to 4/22/25	1 Month Ago 3/23/24 to 3/23/25	3 Months Ago 1/23/24 to 1/22/25	1 Year Ago 4/23/23 to 4/22/24
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	2 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	7 Buy rating(s)	6 Buy rating(s)	3 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$86.80	$89.75	$89.75	$80.00
Forecasted Upside	28.10% Upside	19.78% Upside	31.60% Upside	14.07% Upside
Consensus Rating	Buy	Buy	Buy	Moderate Buy

AZN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

AZN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

AstraZeneca Stock vs. The Competition

Type	AstraZeneca	Medical Companies	S&P 500
Consensus Rating Score	3.09	2.82	2.54
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	27.77% Upside	2,825.80% Upside	26.27% Upside
News Sentiment Rating	Positive News See Recent AZN News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
4/15/2025	BNP Paribas 3 of 5 stars	P. Verdult Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$75.00	+11.09%
2/13/2025	UBS Group 3 of 5 stars	M. Weston Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy
2/12/2025	Morgan Stanley 3 of 5 stars		Initiated Coverage	Overweight
11/6/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Sell ➝ Hold
9/11/2024	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy
8/12/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$90.00 ➝ $95.00	+16.29%
6/24/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Verdult Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/24/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Field Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/30/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$80.00 ➝ $85.00	+10.72%
5/30/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$97.00	+27.50%
4/26/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$80.00 ➝ $82.00	+8.70%
1/3/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
12/18/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 01:40 PM ET.

Should I Buy AstraZeneca Stock? AZN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, April 20, 2025. Please send any questions or comments about these AstraZeneca pros and cons to contact@marketbeat.com.

AstraZeneca
Bull Case

Here are some ways that investors could benefit from investing in AstraZeneca:

AstraZeneca has recently seen a significant increase in institutional investment, with Causeway Capital Management raising its holdings by nearly 70%, indicating strong confidence in the company's future performance.
The stock has received multiple upgrades from analysts, with a consensus rating of "Buy" and an average price target of approximately $86.80, suggesting potential for price appreciation.
The current stock price is around $67.54, which may present a buying opportunity for investors looking to enter at a lower price point before potential gains.
AstraZeneca's diverse portfolio of products, including recent advancements in oncology and respiratory treatments, positions the company well for future growth in the pharmaceutical market.
With 20.35% of the stock owned by institutional investors, there is a level of stability and support that can be attractive to individual investors.

AstraZeneca
Bear Case

Investors should be bearish about investing in AstraZeneca for these reasons:

Despite recent upgrades, the stock has experienced volatility, with a 1-year low of $61.24, which may raise concerns about its stability in the short term.
The pharmaceutical industry is highly competitive, and AstraZeneca faces challenges from other companies that may impact its market share and profitability.
Recent trading volumes have been below average, which could indicate a lack of investor interest or confidence in the stock at this time.
While institutional ownership is significant, it also means that large investors can influence stock price movements, which may not always align with the interests of smaller investors.
Potential regulatory challenges and the need for ongoing investment in research and development can strain financial resources, impacting overall profitability.

AZN Forecast - Frequently Asked Questions

: According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for AstraZeneca is $86.80, with a high forecast of $97.00 and a low forecast of $75.00.
: 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last twelve months. There is currently 1 hold rating, 8 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AZN shares.
: According to analysts, AstraZeneca's stock has a predicted upside of 28.10% based on their 12-month stock forecasts.
: Over the previous 90 days, AstraZeneca's stock had 1 upgrade by analysts.
: AstraZeneca has been rated by research analysts at BNP Paribas, Morgan Stanley, and UBS Group in the past 90 days.
: Analysts like AstraZeneca more than other "medical" companies. The consensus rating for AstraZeneca is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how AZN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:AZN) was last updated on 4/22/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AstraZeneca (AZN) Stock Forecast & Price Target